Compare Schwab US Dividend Equity ETF (SCHD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Tango Therapeutics Inc. — how do they compare? Schwab US Dividend Equity ETF trades at $33.9 (market cap $111.61B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Schwab US Dividend Equity ETF is far larger — about 29.8× Tango Therapeutics Inc.'s market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 64 Days and Tango Therapeutics Inc. for 0 Days on average.
| SCHD | TNGX | |
|---|---|---|
Market Cap | $111.61B | $3.75B |
Volume | 22,238,193 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $32.90 |
52-Week Low | $26.44 | $7.50 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.37, up 0.33% with a bullish technical signal from moving averages. Recent news highlights SCHD outperforming the S&P 500 in 2026 and growing its dividend. The ETF's defensive dividend strategy faces scrutiny after missing gains from stocks like Broadcom due to its selection rules.
The outlook remains positive for income investors seeking quality dividend growth with lower risk through diversification. Key risks include interest rate sensitivity and the opportunity cost of excluded high-growth stocks. Current technical strength supports near-term stability.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
